Does acute treatment with soluble guanylyl cyclase (sGC) activator improve cardiomyocyte function in hypertensive rats with diastolic dysfunction and human heart failure patients?
Acute treatment with an sGC activator improves cardiomyocyte function and signaling pathways, suggesting potential as a treatment for HFpEF.
Our data show that sGC activator improves cardiomyocyte function, reduces inflammation and oxidative stress, improves sGC-PKG signaling, and normalizes hypertrophic kinases, indicating that it is a potential treatment option for HFpEF patients and perhaps also for cases with increased hypertrophic signaling.
Kolijn et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: